Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders Forum
22 January 2014 - 11:00PM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. John
Hunter of Compugen USA, Inc. will present at the Washington
BioLeaders Forum 2014 to be held next week in Washington, D.C. In
his talk, which is scheduled for January 28 in the Phacilitate
Immunotherapy Forum track, Dr. Hunter will demonstrate how Compugen
has applied its predictive discovery platforms to identify novel
immune checkpoints for targeted antibody immunotherapy in cancer.
Validation data for representative targets discovered by the
Company will also be presented. Dr. Hunter is Site Head & Vice
President, Antibody Research & Development at Compugen USA,
Inc., a wholly owned subsidiary of Compugen Ltd.
The Immunotherapy Forum 2014, which in previous years was held
in Barcelona, is an annual international conference focusing on key
emerging trends in novel immunotherapeutic modalities, including
checkpoint inhibitors, adoptive T-cell therapies, other cancer
vaccine technologies and oncolytic virus therapeutics. This is the
first year that the forum is being held as part of the annual
Washington BioLeaders Forum.
About CompugenCompugen is a leading drug discovery
company focused on therapeutic proteins and monoclonal antibodies
to address important unmet needs in the fields of immunology and
oncology. The Company utilizes a broad and continuously growing
integrated infrastructure of proprietary scientific understandings
and predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in silico (by
computer) prediction and selection of product candidates, which are
then advanced in its Pipeline Program. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. In 2012, Compugen established operations in
California for the development of oncology and immunology
monoclonal antibody therapeutic candidates against Compugen drug
targets. For additional information, please visit Compugen's
corporate website at www.cgen.com.
Compugen Ltd.Tsipi Haitovsky, Global Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From May 2023 to May 2024